Marc Beer was recently named by LumeNXT as the company’s new Chairman of the Board. The privately-held company is dedicated to developing proprietary surgical illumination products to enhance the efficiency of minimally-invasive surgeries. He brings over 25 years of experience in development and commercialization in biotechnology, pharmaceuticals, diagnostics, as well as devices.
According to the leader in the healthcare sector, he feels privileged to be working with a group of highly successful and disruptive surgeons as well as engineers who have played a big role in the advancements that have been realized in the surgical illumination field. They have also been a strong part of the development of LumeNXT proprietary technology which has gone a long way into elevating the safety of minimally-invasive surgery. Marc Beer believes that the LumeNXT platform will to receiving more recognition as more surgeries are conducted leveraging minimally invasive techniques.
Surgeons that have had the privilege of using the targeted illumination have attested to its efficiency in enhancing visualization, precision, as well as flexibility when performing operations. The LumeNXT’s illumination platform has a heat reduction system which is designed to improve low-cost disposable options, surgical precision, as well as safety via enhanced visualization.
In a statement, LumeNXT’s Co-Founder, Paul Rhyne praised Marc Beer’s accomplishments and welcomed him on board. Marc Beer has a track record of impressive results in leading companies to success from the ground. The vast experience he boasts in starting and guiding startups to success will be valuable to LumeNXT. His capabilities to guide companies throughout global commercial rollout along the path to achieving their goals and profitability is unmatched.
In addition to his many professional endeavors, he is the Founding Chairman as well as CEO of Renovia, Inc., a healthcare startup which was founded to develop therapeutic and diagnostic products for the treatment of pelvic floor disorders in women. Prior to Founding Renovia, Marc Beer served at Minerva Neurosciences Inc., a biopharmaceutical company which is focused on products that treats central nervous system diseases. He is the retired Founding Chairman of the clinical-stage biopharmaceutical company. Minerva is performing various clinical trials and developing disruptive therapeutic compounds for major depressive disorders, schizophrenia, insomnia as well as mood disorders, as well as Parkinson’s disease.
Prior to founding Minerva, Mr. Marc Beer held several leadership roles in the biopharmaceuticals field. He has been in charge of various commercial launches designed to address rare and debilitating disease globally, initial public offerings, global growth, acquisitions and much more. Some of the positions Beer has held previously include: Former CEO of ViaCell, Genzyme’s Vice President of Global Marketing, member of Erytech Pharma’s board of directors, Good Start Genetics, Inc.’s Founding Chairman of the board, as well as several marketing and sales roles at Abbott Laboratories. Learn more: https://renoviainc.com/